Aliaxis (094124352) AGM 2026 summary

Opening remarks and agenda

• The meeting agenda included management and auditor reports, approval of 2025 annual accounts, profit allocation, discharge of directors and auditor, and miscellaneous items.

Financial performance review

• Net sales for 2025 were €3.5 billion, down 6.8% from 2024 on a like-for-like basis.

• REBITDA was €364 million (10.3% margin), a 30.8% decrease from 2024.

• Net recurring profit was €50 million, down 79.2% from 2024.

• Fixed costs reduced by €58.1 million (-5%) to €1,082 million.

• Non-recurring items totaled €151 million, mainly due to flood costs, restructuring, and asset impairments.

• Capex normalized to €197 million, with working capital improved by €198 million and DSO reduced by 11 days.

• Net financial debt decreased by €50 million to €919 million, with leverage at 2.5x REBITDA.

Board and executive committee updates

• The executive committee as of January 2026 included new and interim appointments, with a focus on transformation and regional leadership.